What Key Contraindications And Pre-Procedure Considerations Must Aesthetic Clinics Evaluate Before Administering Er:yag Laser Resurfacing? Essential Safety Checklist

Before administering Er:YAG laser resurfacing, aesthetic clinics must screen for impaired healing, infection, scarring risk, medication exposure, skin phototype, and patient suitability. Treatment should be postponed or avoided when there is an active infection, suspicious lesion, active keloid tendency, recent systemic isotretinoin use, compromised skin appendages, or an inability to follow aftercare. Periorbital procedures also require specific assessment of lower-eyelid laxity because excessive laxity increases ectropion risk.

Er:YAG resurfacing is safest when the treatment area can re-epithelialize normally, the patient understands the likely outcome and recovery, and modifiable risks have been addressed. Clinics should distinguish absolute contraindications from relative risks that require modified parameters, test spots, additional prophylaxis, or postponement.

Screen for Conditions That Make Treatment Unsafe

Active infection or inflammation

Active bacterial, viral, or fungal infection in the treatment field is a contraindication because ablation can worsen infection and delay healing. Treatment should also be deferred for active inflammatory lesions, significant acne flares, or other untreated skin conditions affecting the planned area.

Patients with a history of herpes simplex, particularly for perioral resurfacing, require a documented antiviral prophylaxis plan. The prescribing clinician should determine the regimen and timing, commonly beginning before treatment and continuing through re-epithelialization.

Suspicious lesions and skin cancer

Suspicious pigmented lesions, non-healing lesions, and active skin cancer in the treatment field must be evaluated before resurfacing. Ablating an undiagnosed lesion can obscure clinical features and delay appropriate diagnosis.

Any lesion that is clinically uncertain should be assessed according to the clinic’s medical protocol before proceeding.

Keloid and hypertrophic scar tendency

A current keloid or active hypertrophic scarring process is a major contraindication to ablative resurfacing. A personal history of abnormal scarring is a significant risk factor, even when no active keloid is present.

For carefully selected patients with a remote history, clinicians may consider conservative settings, a small test spot, and enhanced follow-up. The patient must understand that resurfacing may provoke additional hypertrophic scarring.

Systemic isotretinoin exposure

Recent oral isotretinoin use is a key pre-procedure concern because it may impair the epithelial appendages needed for re-epithelialization and increase the risk of delayed healing or abnormal scarring.

The primary reference identifies the preceding 6 months as a contraindication period, while supporting references describe protocols ranging from 6 to 12 months or longer, depending on treatment depth and product guidance. Clinics should use the prescribing physician’s advice, device labeling, current evidence, and local protocol; deep full-field ablation should not proceed until the required interval has elapsed.

Evaluate Whether the Skin Can Heal Normally

Reduced adnexal structures

Hair follicles and sebaceous glands provide important cellular sources for epidermal repair. Skin with reduced or absent adnexal structures may heal unpredictably after ablation.

Particular caution is required over burn scars, scleroderma-affected skin, previously irradiated areas, and sites with extensive prior dermabrasion, deep peels, or deep laser treatment.

Thin or fibrotic dermis

Long-term use of dermis-thinning agents, including topical retinoids or glycolic acid, may reduce tissue resilience. The clinician should document the treatment history and consider whether the planned depth is appropriate.

Existing fibrosis from previous procedures can also alter laser response and healing. Treatment may require lower energy, reduced density, a test area, or postponement while the skin recovers.

Vascular and systemic healing risks

Smoking can compromise tissue perfusion and increase the risk of delayed healing or necrosis. Diabetes and other conditions affecting microvascular function also require careful medical assessment.

Autoimmune or collagen vascular diseases, including scleroderma, lupus, and Sjögren syndrome, may produce unpredictable wound healing. Previous head or neck radiation can create similar microvascular and tissue-quality concerns.

These factors do not always carry the same risk in every patient or treatment pattern, so the clinician must determine whether treatment should be avoided, modified, or referred for additional medical evaluation.

Assess Skin Type and Treatment Area

Fitzpatrick skin type

Skin phototype is central to risk assessment because darker skin is more susceptible to post-inflammatory hyperpigmentation and persistent dyschromia after deeper ablation.

Patients with Fitzpatrick types IV to VI generally require especially conservative planning. Superficial or fractional approaches may be more appropriate than deep full-field resurfacing, with careful parameter selection and strict photoprotection.

Existing pigmentation disorders

Severe pre-existing hyperpigmentation or active melasma can worsen after resurfacing. Active melasma is identified in the supporting references as a contraindication, while a history of dyschromia represents a risk requiring counseling and protocol modification.

The clinician should establish whether pigment instability is active, controlled, or likely to be aggravated by the proposed treatment.

Periorbital anatomy

Lower-eyelid laxity must be assessed before periorbital resurfacing. Reduced elasticity increases the risk of postoperative ectropion, in which the eyelid turns outward and may expose the ocular surface.

The examination should include eyelid position, laxity, and other factors relevant to ocular protection. A high-risk patient may require a different treatment plan or should not undergo periorbital ablation.

Confirm Patient Readiness

Expectations and motivation

The patient should understand the realistic degree of improvement, the limitations of resurfacing, the expected recovery period, and the possibility of complications. A mismatch between expectations and likely results is a contraindication because technically successful treatment may still produce an unacceptable outcome.

Consultation should address whether the patient seeks improvement in dyschromia, texture, photoaging, rhytids, or acne and traumatic scars, and whether Er:YAG depth and modality are suitable for that goal.

Compliance with aftercare

Healing depends on wound care, infection prevention, follow-up, and sun avoidance. Patients who cannot commit to prescribed care, including prolonged and strict sun protection, may face avoidable complications and should not proceed until this issue is resolved.

The clinic should confirm access to follow-up and the patient’s ability to recognize concerning symptoms such as worsening pain, infection, delayed epithelialization, or abnormal scarring.

Medication and procedure history

The review should include oral and topical retinoids, recent chemical peels, dermabrasion, electrolysis, prior laser treatment, corticosteroid injections, and other procedures affecting the treatment area. Recent extensive electrolysis or destructive procedures may have reduced the follicular structures needed for healing.

The record should also capture smoking, diabetes, immune status, autoimmune disease, prior radiation, herpes simplex history, and previous abnormal scarring.

Understanding the Trade-offs

Deeper treatment increases risk

Deeper full-field resurfacing can address more pronounced texture, rhytids, or scarring, but it places greater demands on re-epithelialization and carries greater risk of delayed healing, infection, dyschromia, and scarring.

Fractional or more superficial treatment may provide less dramatic correction but can be a more appropriate risk-adjusted option for darker phototypes, compromised skin, or patients with relative contraindications.

Er:YAG does not eliminate screening requirements

Er:YAG is commonly used for superficial dyschromia, coarse texture, photoaging, rhytids, and acne or traumatic scarring. Its tissue interaction may reduce some demarcation concerns compared with other ablative approaches, but it remains an ablative procedure with meaningful wound-healing risks.

Device selection does not compensate for active infection, recent isotretinoin use, poor tissue quality, unrealistic expectations, or inadequate aftercare.

Relative contraindications need documented decisions

A history of smoking, diabetes, herpes simplex, autoimmune disease, darker phototype, eyelid laxity, or prior tissue injury does not automatically produce the same recommendation for every patient. These factors should trigger individualized risk assessment, conservative settings, prophylaxis where indicated, test spots, or referral.

The decision and rationale should be documented rather than treating “relative contraindication” as either an automatic approval or an automatic refusal.

Making the Right Choice for Your Goal

A structured consultation should connect the patient’s objective with the safest effective treatment plan.

If your primary focus is maximum resurfacing effect: Confirm normal tissue-healing capacity, exclude infection and recent isotretinoin exposure, and ensure the patient accepts the recovery and complication risks of deeper treatment.
If your primary focus is minimizing pigment or scarring risk: Consider superficial or fractional treatment, particularly for darker Fitzpatrick phototypes or patients with prior dyschromia and abnormal scarring.
If your primary focus is periorbital correction: Assess lower-eyelid laxity and ocular risk before selecting treatment depth or proceeding.
If your primary focus is scar revision: Evaluate scar behavior, prior procedures, adnexal structures, and the possibility of a conservative test spot before treating the full area.
If your primary focus is predictable recovery: Address smoking, systemic disease, medication history, infection risk, sun exposure, and aftercare compliance before scheduling treatment.

The safest Er:YAG resurfacing decision is the one that matches treatment depth to the patient’s healing capacity, anatomy, expectations, and ability to complete aftercare.

Summary Table:

Consideration	Key Points
Active infection/inflammation	Postpone treatment; antiviral prophylaxis for herpes history
Suspicious lesions	Evaluate before ablation; avoid obscuring diagnosis
Keloid/scar tendency	Avoid if active; conservative approach if remote history
Isotretinoin use	Wait 6-12 months after stopping; consult physician
Skin healing capacity	Assess adnexal structures, fibrosis, vascular health
Skin type/pigmentation	Darker types (IV-VI) need conservative settings; active melasma is contraindication
Periorbital anatomy	Check eyelid laxity to prevent ectropion
Patient readiness	Realistic expectations, compliance with aftercare, full history

Ensure your clinic's safety protocols meet the highest standards. At BELIS, we provide advanced Er:YAG and other aesthetic laser systems designed for professional use in clinics and premium salons. For expert guidance on safe and effective treatments, contact us today to discuss your requirements and discover how our technology can enhance your practice. Contact us now to learn more about our comprehensive product portfolio, including laser, IPL, and body sculpting solutions, and our support for distributors and clinics.